BURR, Randon Michael,AMBATI, Balamurali K.,MOLOKHIA, Sarah A.
申请号：
AU2019205774
公开号：
AU2019205774A1
申请日:
2019.01.07
申请国别(地区):
AU
年份:
2020
代理人:
摘要：
An ophthalmic composition or dosage form can include a therapeutically effective amount of a copper-containing agent that is sufficient to increase corneal lysyl oxidase activity in an eye of a subject in an amount sufficient to treat myopic progression and a pharmaceutically acceptable carrier. The composition or dosage form can be used to treat or prevent progression of myopia by administering a therapeutically effective amount of the composition to an eye of a subject during a treatment period.
